Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity

RORγt is the key transcription factor controlling the development and function of CD4(+) Th17 and CD8(+) Tc17 cells. Across a range of human tumors, about 15% of the CD4(+) T cell fraction in tumor-infiltrating lymphocytes are RORγ+ cells. To evaluate the role of RORγ in antitumor immunity, we have...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncoimmunology
Autores principales: Hu, Xiao, Liu, Xikui, Moisan, Jacques, Wang, Yahong, Lesch, Charles A., Spooner, Chauncey, Morgan, Rodney W., Zawidzka, Elizabeth M., Mertz, David, Bousley, Dick, Majchrzak, Kinga, Kryczek, Ilona, Taylor, Clarke, Van Huis, Chad, Skalitzky, Don, Hurd, Alexander, Aicher, Thomas D., Toogood, Peter L., Glick, Gary D., Paulos, Chrystal M., Zou, Weiping, Carter, Laura L.
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2016
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5215247/
https://ncbi.nlm.nih.gov/pubmed/28123897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1254854
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares